6,229
Views
6
CrossRef citations to date
0
Altmetric
Psychiatry

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

, , , , , & show all
Pages 875-882 | Received 29 Aug 2019, Accepted 23 Jan 2020, Published online: 13 Feb 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yen Kuang Yang, Cheng-Sheng Chen, Chia-Fen Tsai, Chia-Ming Chang, Te-Jen Lai, Chun-Te Lee, Chih-Chien Lin, Tsuo-Hung Lan & Keira Joann Herr. (2021) A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Current Medical Research and Opinion 37:12, pages 2163-2173.
Read now
Dorota Danielak. (2021) Vortioxetine in management of major depressive disorder – a favorable alternative for elderly patients?. Expert Opinion on Pharmacotherapy 22:9, pages 1167-1177.
Read now

Articles from other publishers (4)

Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, Valerio Caruso, Icro Maremmani, Stefano Pini & Giulio Perugi. (2024) The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature. Journal of Clinical Medicine 13:2, pages 531.
Crossref
Yared Belete Belay, Lidia Engel, Yong Yi Lee, Ngoc Le & Cathrine Mihalopoulos. (2023) Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review. PharmacoEconomics 41:6, pages 651-673.
Crossref
Xiaolin Ye, Dong Wang, Huaqian Zhu, Dahai Wang, Jing Li, Yanqing Tang & Jie Wu. (2021) Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. Frontiers in Psychiatry 12.
Crossref
. (2020) Vortioxetine in major depression: high success rates, acceptable cost. PharmacoEconomics & Outcomes News 846:1, pages 31-31.
Crossref